GE to acquire Thermo Fisher units for $1.06 bn

Jan 06, 2014

General Electric plans to acquire cell research divisions from Thermo Fischer Scientific for $1.06 billion to boost the conglomerate's health unit, the companies announced Monday.

Under the transaction, GE Healthcare will buy Thermo Fisher cell research businesses to further efforts to develop major new medicines and vaccines in .

GE said the deal would enhance its "bioprocessing footprint in Asia, the Americas and Europe."

Cell culture plays a major role in the manufacturing of medicines to treat cancer, rheumatoid arthritis and other ailments, GE said. GE will also boost its technologies in protein analysis with the deal.

"Life Sciences is one of our strongest and fastest-growing business areas, driven by the world's demand for improved diagnostics and new, safer medicines," said John Dineen, chief executive of GE Healthcare.

"This deal makes a good business even better and will help us realize our vision of bringing better healthcare to more people at lower cost."

GE recently announced plans to spin off its North American retail finance business as it seeks to emphasize its industrial business.

Explore further: EU approves Thermo Fisher buy of Life Technologies

add to favorites email to friend print save as pdf

Related Stories

EU approves Thermo Fisher buy of Life Technologies

Nov 26, 2013

European regulators have approved scientific instrument maker Thermo Fisher Scientific Inc.'s $13.6 billion acquisition of Life Technologies Corp., on the condition that they divest parts of their businesses.

Imec demonstrates strained germanium finFETs at IEDM 2013

Dec 11, 2013

At this week's IEEE International Electron Devices Meeting (IEDM 2013), imec reported the first functional strained germanium (Ge) quantum-well channel pMOS FinFETs, fabricated with a Si Fin replacement process on 300mm Si ...

Recommended for you

Line says no IPO this year

14 hours ago

The Japan-based operator of popular mobile messaging app Line said Monday it has decided not to go ahead with an initial public offering in Japan or overseas this year.

User comments : 0